Importance: Robotic assistance in pelvic organ prolapse surgery can improve surgeon ergonomics and instrument dexterity compared with traditional laparoscopy but at increased costs.
Objective: To compare total costs for robotic-assisted sacrocolpopexy (RSC) between two robotic platforms at an academic medical center.
Methods: Retrospective cohort of Senhance (Ascensus) RSC between 1/1/2019 and 6/30/21 who were matched 2:1 with DaVinci (Intuitive) RSC. Primary outcome was total costs to hospital system; secondarily we evaluated cost sub-categories. Purchase costs of the robotic systems were not included. T-test, chi-square, and Fisher's exact tests were used. A multivariable linear regression was performed to model total costs adjusting for potential confounders.
Results: The matched cohort included 75 subjects. The 25 Senhance and 50 DaVinci cases were similar overall, with mean age 60.5 ± 9.7, BMI 27.9 ± 4.7, and parity 2.5 ± 1.0. Majority were white (97.3%) and postmenopausal (86.5%) with predominantly stage III prolapse (64.9%). Senhance cases had longer OR times (Δ = 32.1 min, p = 0.01). There were no differences in concomitant procedures, intraoperative complications, or short-term postoperative complications between platforms (all p > 0.05). On univariable analysis, costs were similar (Senhance $5368.31 ± 1486.89, DaVinci $5741.76 ± 1197.20, p = 0.29). Cost subcategories (medications, supplies, etc.) were also similar (all p > 0.05). On multivariable linear regression, total cost was $908.33 lower for Senhance (p = 0.01) when adjusting for operative time, estimated blood loss, concomitant mid-urethral sling, and use of the GelPoint mini port system.
Conclusions: Despite longer operating times, total cost of robotic-assisted sacrocolpopexy was significantly lower when using the Senhance compared to the DaVinci system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00192-022-05391-3 | DOI Listing |
J Minim Invasive Gynecol
December 2024
Department of Obstetrics and Gynecology (Drs. Zhang, Jiang, Mao, Bai, Tian, and Guo), The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:
Objective: To compare the long-term efficacy of conventional laparoscopic sacrocolpopexy with those of robot-assisted laparoscopic sacrocolpopexy in the treatment of pelvic organ prolapse.
Design: Retrospective cohort study.
Setting: Tertiary referral center in China.
BMC Surg
December 2024
Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, 892, Dongnam-ro, Gangdong-gu, Seoul, 134-727, Korea.
Int Urogynecol J
November 2024
Department of Obstetrics and Gynecology, University of Liège, Hospital La Citadelle, Boulevard du 12 e de Ligne, n°1, 4000, Liège, Belgium.
Urology
October 2024
Minimally Invasive Urology Institute, The Miriam Hospital; The Warren Alpert Medical School of Brown University, Providence, RI.
J Minim Invasive Gynecol
December 2024
Mackay Medical College, New Taipei, Institute of Translational Medicine and New Drug Development (Dr. Lin); College of Medicine, China Medical University, Taichung, Department of Physiology, School of Medicine (Dr. Lin); College of Medicine, Taipei Medical University, Taipei, and Graduate Institute of Biomedical Electronics and Bioinformatics (Dr. Lin), National Taiwan University, Taipei, Taiwan.. Electronic address:
Study Objective: Although mean/static compliance of bladder filling can be readily assayed via cystometry, a protocol measuring compliance dynamics at a specific stage of bladder filling has not been established in human patients. For patients with pelvic organ prolapse (POP), the objective benefits of robotic-assisted sacrocolpopexy (RSCP) surgical intervention for restoring bladder functions, primarily urine storage, have yet to be established. Also, bladder compliance is a viscoelastic parameter that crucially defines the storage function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!